Treatment of therapy-resistant acral ulcers with iloprost;Behandlung therapieresistenter akraler ulzera mit iloprost

Hautarzt

Volumn 55, Issue 12, 2004, Pages 1150-1153

  Von Schmiedeberg, S ^a   Artik, S ^a   Assmann, T ^a   Megahed, M ^a   Ruzicka, T ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Acral ulcers; Iloprost infusion; Raynaud phenomenon; Systemic sclerosis

Indexed keywords

ILOPROST;

ADULT; AMPUTATION; ARTICLE; CASE REPORT; DRUG EFFECT; GANGRENE; HUMAN; NECROSIS; RAYNAUD PHENOMENON; SKIN ULCER; SYSTEMIC SCLEROSIS;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FINGERS; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NECROSIS; RECURRENCE; SCLERODERMA, SYSTEMIC; SKIN ULCER; TREATMENT OUTCOME;

EID: 11244328199     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-004-0844-y     Document Type: Article

References (20)

1. Casas JA, Saway PA, Villareal I, Nolte C (1990) 5-fluoro-uracil in the treatment of scleroderma: a randomized, double-blind, placebo-controlled international collaborative study. Ann Rheum Dis 49:926-931
2. Clements PJ (1995) Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 7:517-551
3. Constans T, Diot E, Lasfregues G (1991) Iloprost for scleroderma. Letter. Ann Intern Med 114:606
4. Cordioli E, Virgilio S, Ghirardi R, Martinelli M (1992) Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis. Minerva Med 83:739-744
5. Crutchley DJ, Conanan LB, Que BG (1994) Effects of prostacyclin analogues on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells. J Pharmacol Exp Ther 271:446-451
6. Della Bella S, Molteni M, Mocellin C et al. (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Lipid Mediators 65:73-83
7. Furst DE, Clements PJ, Hillis S et al. (1989) Immunosuppression with chlorambucil vs placebo for scleroderma: results of a three year, parallel, randomized, double-blind study. Arthritis Rheum 32:584-589.
8. Genth E, Mierau R, Genetzky P et al. (1990) Immunogenetic association of scleroderma-related antinuclear antibodies. Arthritis Rheum 33:657-665
9. Gröchenig E (2002) Gefäßmedizin. ABW Wissenschaftsverlag, Berlin Leiben, S 94-96
10. Jimenez SA, Sigal SH (1991) A 15 year-prospective study of treatment of rapidly, progressive systemic sclerosis with D-penicillamine. J Rheumatol 18:1496-1501
11. Kahaleh B, Matucci-Cerinic M (1995) Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 38:1-4
12. Krieg T, Meurer M (1988) Systemic scleroderma. Clinical and pathophysiologic aspects. J Am Acad Dermatol 18:457-481
13. LeRoy EC (1992) A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 51:286-288
14. Rademaker M, Thomas RHM, Provost G et al. (1987) Prolonged increased blood flow following iloprost infusion in systemic sclerosis. Postgrad Med J 63:617-620
15. Rademaker M, Almond NE, Beachman JA et al. (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Br Med J 298:561-564
16. Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprostgabe über 21 Tage als wirksame Therapie bei der progressiven systemischen Sklerodermie - Fallbeschreibung und Literaturübersicht. Z Rheumatol 57:118-124
17. Righi A, Matucci Cerinic M (2002) New treatments in scleroderma: the rheumatologic perspective. JEADV 16:431-432
18. Rodnan RP, Myerowitz RL, Justh GO (1980) Morphologie changes in digital arteries of progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine 59:393-408
19. Seibold JR, Furst DE, Clements PJ (1992) Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol 19:673-667
20. Wighley FM, Sule SD (2001) Novel therapy in the treatment of scleroderma. Exp Opin Invest Drug 101:31-48